Over the past weeks, LUPUS EUROPE and several of its members have worked to improve availability of Hydroxychloroquine for people with lupus in Europe, as speculations on its possible use for COVID treatment have resulted in an increased (off-label) demand.

Our objective is that all patients with a chronic condition requiring Hydroxychloroquine have access, if not immediately, at least  within 3 days of ordering.

We now need to verify that our efforts are indeed resulting in an improved access, and remain qadequate the future. We therefore need your feedback: If you are a Patient using hydroxychloroquine, last time you purchased it, did you get your normal quantity when you asked in your pharmacy?

Please help us by filling this very short survey (available in several languages) https://www.surveylegend.com/s/25nh and send this link to all your lupus friends asking them to participate. then ,next time you buy Hydroxychloroquine, come back to this link and tell us again. It is only if many of you (not just those that have access issues) participate that we will be able to read relevant results, and focus the additional work where it possibly still is needed.

TAKE THE SURVEY HERE

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

🚨 New publication alert: EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement- 2025 update.

‼️ According to Lupus Europe's 2024 Swiss knife survey:

1️⃣ Kidney involvement remains one of the most worrying and impactful lupus manifestations for many people in Europe.
2️⃣ Kidney problems are among the manifestations causing the greatest long-term concern.
3️⃣ Only a small minority of patients report long-term stability without flares.
4️⃣ Patients want clearer goals, better communication, and care that looks beyond lab values alone.

That is why the 2025 update of the EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement is such an important step forward.

✅ These updated recommendations reinforce several key messages that matter to patients:
- Early and regular monitoring of kidney involvement.
- Timely kidney biopsy when needed.
- Clear treatment targets to preserve kidney function.
- A strong focus on combination therapies when appropriate.
- Long-term kidney protection, not only short-term control.

🌟 We are especially proud that our Chair, Jeanette Andersen, was part of the international task force that developed these recommendations, ensuring that the patient perspective was present at the table.

You can read the EULAR Recommendations here: ard.eular.org/article/S0003-4967(25)04412-7/fulltext

And the Swiss Knife Survey here: www.sciencedirect.com/science/article/pii/S1568997225000989
... See MoreSee Less

🚨 New publication

😃 Thank you to all who attended our latest Youth Group webinar!

🌟 So many interesting questions were asked and addressed! Showing how important safe spaces arefor talking openly about lupus without judgment.

Did you miss it? Watch it here! 👇

Alcohol & Drugs - Lupus
... See MoreSee Less

😃 Thank you to al

🚨 𝗟𝗮𝘀𝘁 𝗰𝗵𝗮𝗻𝗰𝗲❗

🙏 Help Prof Laurent Arnaud and his team validate the Lupus Brain Fog Severity Scale.

✅ Make lupus brain fog measurable.

⏱️ 5 minutes of your time can make a huge impact!

lupusresearch.limequery.org/337533?lang=en
... See MoreSee Less

🚨 𝗟𝗮𝘀�
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send